BRPI0409170A - combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos - Google Patents

combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos

Info

Publication number
BRPI0409170A
BRPI0409170A BRPI0409170-1A BRPI0409170A BRPI0409170A BR PI0409170 A BRPI0409170 A BR PI0409170A BR PI0409170 A BRPI0409170 A BR PI0409170A BR PI0409170 A BRPI0409170 A BR PI0409170A
Authority
BR
Brazil
Prior art keywords
combinations
treatment
neurological disorders
antiepileptic drugs
drugs
Prior art date
Application number
BRPI0409170-1A
Other languages
English (en)
Portuguese (pt)
Inventor
David Aitken
Kurt Lingenh Hl
Markus Schmutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0409170A publication Critical patent/BRPI0409170A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI0409170-1A 2003-04-04 2004-04-02 combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos BRPI0409170A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
BRPI0409170A true BRPI0409170A (pt) 2006-04-11

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409170-1A BRPI0409170A (pt) 2003-04-04 2004-04-02 combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos

Country Status (10)

Country Link
US (1) US20060194766A1 (enExample)
EP (1) EP1620103A1 (enExample)
JP (1) JP2006522062A (enExample)
CN (1) CN100546581C (enExample)
AU (1) AU2004226825B2 (enExample)
BR (1) BRPI0409170A (enExample)
CA (1) CA2521274A1 (enExample)
GB (1) GB0307860D0 (enExample)
MX (1) MXPA05010707A (enExample)
WO (1) WO2004087161A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
IT1261808B (it) * 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
WO1998017692A1 (en) * 1996-10-19 1998-04-30 University Of Wales, Bangor Preparation of chemically reactive polysaccharides
TR199900897T2 (xx) * 1996-10-24 1999-07-21 Novartis Ag Ornat�lm�� aminoalkanfosfonik asitler.
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
IL149530A0 (en) * 1999-12-01 2002-11-10 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
KR20050044396A (ko) * 2001-11-12 2005-05-12 노파르티스 아게 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀

Also Published As

Publication number Publication date
AU2004226825B2 (en) 2007-08-16
MXPA05010707A (es) 2005-12-12
WO2004087161A1 (en) 2004-10-14
CA2521274A1 (en) 2004-10-14
JP2006522062A (ja) 2006-09-28
GB0307860D0 (en) 2003-05-14
AU2004226825A1 (en) 2004-10-14
EP1620103A1 (en) 2006-02-01
US20060194766A1 (en) 2006-08-31
CN100546581C (zh) 2009-10-07
CN1767832A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
BR0213358A (pt) Uso de flibanserina
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
MY125821A (en) Pharmaceutical composition of topiramate
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
BRPI0512242A (pt) derivados de sulfamato e sulfamida úteis para o tratamento de epilepsia e distúrbios relacionados
IL176689A0 (en) Use of memantine for the preparation of a medicament for the treatment of mild and mild-to-moderate alzheimer's disease
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2005035485A3 (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
CA2583764A1 (en) Thrombopoietin activity modulating compounds and methods
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
EP2161037A3 (en) Camptothecin-Somatostatin conjugates
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
BR0210650A (pt) Tablete, e, uso do mesmo
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
BRPI0415123A (pt) uso de l-butilftalida e respectiva composição farmacêutica
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BRPI0409170A (pt) combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos
WO2005077343A3 (de) Neue arzneimittel und diagnostische zusammensetzungen für behandlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.